Clinical Trial Update: Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update for Phase 1/Phase 2 evaluation of molecular imaging of the DNA damage response using the [18F]-labeled Olaparib PET tracer in he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Olaparib (Olaparib)
• [18F]-Olaparib PET imaging agent (18F-labeled olaparib)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING